Federation Des Caisses Desjardins Du Quebec Vaxcyte, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.4 Billion
- Q4 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 56 shares of PCVX stock, worth $2,114. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56
Previous 56
-0.0%
Holding current value
$2,114
Previous $6,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
349Shares Held
126MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$452 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$399 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$375 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$328 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$235 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.24B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...